I try, often unsuccessfully, to not post while on vacation but this is just too important. Hot of the @adasarimd et al. press. New SEER data. Increasing incidence and prevalence, owing to earlier and likely largely incidental diagnoses. Improving OS too🙂
https://t.co/l7KyQdFMtK
Proud to be a contributing author. ASCO Releases Its First Guideline to Support Oncologists in Managing Symptoms of Gastroenteropancreatic Neuroendocrine Tumors @ASCO@NANETS1@snmmi@ICPO_Foundation@CureNETs https://t.co/Tz91OXdQOU
Are they kind? That was the ? posed to me dressings rm while waiting for my MRI. This was after a tech used tape to keep my socks on. I told her they were and that it was 50th scan and that all imaging techs over my 17 year+ journey have been kind. So let's all be kind this year
@oreganruth@Nate_WilsonMD@AACR@ASCO Another year of working with and learning from some great learners. You will all leave San Diego tomorrow with completed protocols and informed consents. Congratulations
Grateful for the opportunity to give my testimony at the #WaysAndMeans Committee’s field hearing in #Utah, focused on access to health care. Honored to represent and share many of my patients’ experiences. @huntsmancancer @NeliMUlrich @HCI_SachApte@HuntsmanCOE
Live Now The Past, Present, and Future of Theranostics for NETs: Richard Baum, MD, Professor of Nuclear Medicine, Elcin Zan, MD, Radiologist, Shereen Ezzat, MD, Endocrinologist, Princess Margaret Cancer Centre - https://t.co/pf1uMrH5jg
@marklewismd@OncoThor@NANETS1@CureNETs@SNM_MI Since I haven't bought the article. It would be interesting to note % of those pretreated with akylators and average time to onset. Given the delay in onset of MDS AML how do you tease out prior therapy? We saw some of these in control net trial when rlt combo with cap tem